| Name | Title | Contact Details |
|---|
Ockham Development Group is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Modern Meadow was founded on the belief that customers should not have to choose between performance and sustainability. Additionally, we believe that people should not have to choose between a career that helps them achieve their personal goals and a career with purpose. Achieving both personal and professional goals with purpose is possible at Modern Meadow, and we invite qualified professionals to apply for positions of interest. At the intersection of biotechnology and material science, Modern Meadow designs materials solutions for the way we want the world to perform. We are pioneers of biofabrication, building with biology. This enbables us to harness unique properties of proteins to move the world away from petrochemical and animal-derived inputs, leading a shift to the bioeconomy. Modern Meadow Biofabricated Materials offer the world a new way forward. By introducing a more effective, more responsible, and readily available supply, we are shifting demand away from extractive practices and toward a sustainable bioeconomy. Our team is engaged in exciting work to enable us all to move beyond sustainability to real world impact. Our philosophy and sustainability principles help us stay focused on the most critical environmental issues and challenge us to design our products and systems in the most sustainable manner. But we cannot build a bioeconomy alone. We are partnering with companies, developing bio-based supply chains, and speaking with businesses looking to design for sustainability from the start. Together we can create new coalitions to build out the environmentally conscious alternatives our planet desperately needs.
Applied Therapeutics is a clinical-stage biopharmaceutical company that uses our novel drug-development approach to create transformative, life-changing treatments for the patients who desperately need them.
Millennium, a leading biopharmaceutical company, applies its comprehensive and integrated science and technology platform for the discovery and development of breakthrough therapeutic and predictive medicine products, with a goal of delivering
We are a clinical-stage biopharmaceutical company focused on discovering and developing best-in-class therapies for patients with liver and gastrointestinal, or GI, diseases. Since our founding in 2014, we have invested in building a foundation of chemistry and biology expertise to drive innovative drug discovery and development. We believe these internal capabilities allow us to gain insights into disease targets and mechanisms and more quickly and purposefully design therapies with characteristics that we view as key to safety and efficacy. With this systematic approach, we have designed novel, proprietary farnesoid X receptor (FXR) clinical product candidates arising from a unique chemical scaffold with the potential to be best-in-class for non-alcoholic steatohepatitis, or NASH, and first- in-class for Inflammatory Bowel Disease, or IBD. In addition to our FXR program, we have continued to invest in drug discovery on other therapeutic targets that have effects on inflammation and/or fibrosis for which we believe we could develop proprietary small molecule therapies.